Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 8:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: HZ/su Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine

NCT05047770
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ/su, Flu D-QIV, mRNA-1273
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
2,013 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
46
States / cities
Tempe, Arizona • Oxnard, California • San Diego, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 5, 2026, 8:44 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers

NCT01767467
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes zoster vaccine (GSK 1437173A), Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
8
States / cities
Inverness, Florida • Chicago, Illinois • Elkhart, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 5, 2026, 8:44 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

NCT01954251
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster vaccine GSK 1437173A, GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
829 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
Phoenix, Arizona • Carnegie, Pennsylvania • Erie, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Sep 5, 2026, 8:44 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age

NCT02075515
View directory record Official record
Conditions
Herpes Zoster, Herpes Zoster Vaccine
Interventions
Herpes Zoster vaccine (GSK 1437173A)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
651 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
3
States / cities
Mesa, Arizona • Wichita, Kansas • Milford, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Sep 5, 2026, 8:44 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults

NCT05966090
View directory record Official record
Conditions
Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccine, HZ/su vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
530 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
11
States / cities
Daphne, Alabama • Tempe, Arizona • Corte Madera, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Sep 5, 2026, 8:44 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults

NCT02723773
View directory record Official record
Conditions
Herpes Zoster, Herpes Zoster Vaccine
Interventions
Herpes Zoster Vaccine GSK1437173A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
7,539 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
25
States / cities
Phoenix, Arizona • Spring Valley, California • Hallandale, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Sep 5, 2026, 8:44 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older

NCT02052596
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster vaccine GSK 1437173A, Boostrix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
935 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
13
States / cities
Tucson, Arizona • San Diego, California • Stockbridge, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Sep 5, 2026, 8:44 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.

NCT02690207
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster Vaccine GSK1437173A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
8,687 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
37
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Sep 5, 2026, 8:44 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older

NCT01751165
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes zoster vaccine GSK1437173A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
354 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
Spring Valley, California • Wichita, Kansas • Uniontown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Sep 5, 2026, 8:44 AM EDT
Terminated No phase listed Observational

Solid Organ Transplant SHINGRIX

NCT03993717
View directory record Official record
Conditions
Kidney Transplant; Complications
Interventions
SHINGRIX
Biological
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 5, 2026, 8:44 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects

NCT01165203
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster Vaccine GSK1437173A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Long Beach, California • San Francisco, California • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2018 · Synced Sep 5, 2026, 8:44 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age

NCT02979639
View directory record Official record
Conditions
Herpes Zoster
Interventions
GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
404 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
11
States / cities
Oakland, California • Aurora, Colorado • Colorado Springs, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Sep 5, 2026, 8:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds

NCT02114333
View directory record Official record
Conditions
Shingles, Herpes Zoster
Interventions
Zostavax, HZ/su vaccine, Placebo
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Sep 5, 2026, 8:44 AM EDT
Recruiting Phase 4 Interventional

Safety of the Herpes Zoster Subunit Vaccine in Lupus

NCT05559671
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Herpes Zoster Subunit (HZ/su) Vaccine, Placebo
Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New York, New York • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Sep 5, 2026, 8:44 AM EDT
Completed No phase listed Observational Results available

A Study to Assess Frailty of Subjects During ZOSTER-006 and ZOSTER-022

NCT03563183
View directory record Official record
Conditions
Herpes Zoster
Interventions
Encoding of data collected in Zoster 006 and Zoster 022 studies
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
26,976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
31
States / cities
Mesa, Arizona • Phoenix, Arizona • Spring Valley, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Sep 5, 2026, 8:44 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older

NCT03439657
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ/su vaccine GSK1437173A, Prevenar13
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
913 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
3
States / cities
Marlborough, Massachusetts • Salisbury, North Carolina • Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 5, 2026, 8:44 AM EDT
Active, not recruiting No phase listed Observational

Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions

NCT05811754
View directory record Official record
Conditions
Herpes Zoster
Interventions
Data collection
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
2,844 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Canton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 5, 2026, 8:44 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults

NCT06890416
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE, HZ/su VACCINE
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
526 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
25
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 5, 2026, 8:44 AM EDT
Active, not recruiting Phase 3 Interventional

A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults

NCT05371080
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ/su vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
3,038 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Phoenix, Arizona • Elkridge, Maryland • Charlotte, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Sep 5, 2026, 8:44 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier

NCT02581410
View directory record Official record
Conditions
Herpes Zoster
Interventions
GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years and older
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
32
States / cities
Huntsville, Alabama • Daly City, California • Los Gatos, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Sep 5, 2026, 8:44 AM EDT